Pharmacological reports : PR最新文献

Unraveling the mechanistic interplay of mediators orchestrating the neuroprotective potential of harmine. 揭示协调荷马碱神经保护潜能的介质的机理相互作用。

Pharmacological reports : PR Pub Date : 2024-05-17 DOI: 10.1007/s43440-024-00602-8

Pankaj Kadyan, Lovedeep Singh

引用次数: 0

Tolerability of N-chlorotaurine in comparison with routinely used antiseptics: an in vitro study on chondrocytes. N-氯牛磺酸与常规防腐剂的耐受性比较：对软骨细胞的体外研究。

Pharmacological reports : PR Pub Date : 2024-05-17 DOI: 10.1007/s43440-024-00601-9

Magdalena Pilz, Kevin Staats, O. Assadian, Reinhard Windhager, J. Holinka

引用次数: 0

Essential phospholipids impact cytokine secretion and alter lipid-metabolizing enzymes in human hepatocyte cell lines. 必需磷脂影响细胞因子的分泌，并改变人肝细胞系中的脂质代谢酶。

Pharmacological reports : PR Pub Date : 2024-04-26 DOI: 10.1007/s43440-024-00595-4

Dominik Wupperfeld, Gert Fricker, Béatrice Bois De Fer, Branko Popovic

引用次数: 0

Role of the β2-adrenergic receptor in podocyte injury and recovery. β2肾上腺素能受体在荚膜细胞损伤和恢复中的作用

Pharmacological reports : PR Pub Date : 2024-04-26 DOI: 10.1007/s43440-024-00594-5

Ehtesham Arif, Ashish Kumar Solanki, Bushra Rahman, Bethany Wolf, Rick G. Schnellmann, D. Nihalani, J. Lipschutz

引用次数: 0

Role of the RAAS in mediating the pathophysiology of COVID-19. RAAS 在介导 COVID-19 病理生理学中的作用。

Pharmacological reports : PR Pub Date : 2024-04-23 DOI: 10.1007/s43440-024-00596-3

J. Jasiczek, Adrian Doroszko, Tymoteusz Trocha, M. Trocha

引用次数: 0

The impact of excessive maternal weight on the risk of neuropsychiatric disorders in offspring-a narrative review of clinical studies. 母亲体重过重对后代患神经精神疾病风险的影响--临床研究综述。

Pharmacological reports : PR Pub Date : 2024-04-22 DOI: 10.1007/s43440-024-00598-1

Magdalena Kacperska, J. Mizera, Maciej Pilecki, L. Pomierny-Chamioło

引用次数: 0

Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population. 波兰人群中接受环孢素A治疗的肾移植患者p -糖蛋白药物转运蛋白MDR1基因多态性

Pharmacological reports : PR Pub Date : 2007-03-01 DOI: 10.1097/00008571-200305000-00004

K. Kotrych, T. Sulikowski, L. Domański, M. Białecka, M. Droździk

{"title":"Polymorphism in the P-glycoprotein drug transporter MDR1 gene in renal transplant patients treated with cyclosporin A in a Polish population.","authors":"K. Kotrych, T. Sulikowski, L. Domański, M. Białecka, M. Droździk","doi":"10.1097/00008571-200305000-00004","DOIUrl":"https://doi.org/10.1097/00008571-200305000-00004","url":null,"abstract":"P-glycoprotein (P-gp), the product of MDR1 gene, is a protein which mediates transmembrane transport of a great number of xenobiotics including cyclosporin A used as an immunosuppressive drug in patients with allogenic kidney grafts. The P-gp activity and expression is dependent on the MDR1 gene polymorphism in position C3435T of exon 26. In this study, C3435T polymorphism was analyzed in 116 patients with allogenic kidney graft treated with cyclosporin Aand 144 randomly selected healthy individuals. The prevalence of MDR1 gene genotypes 3435CC, 3435CT, 3435TT were also compared in patients after allogenic kidney graft with both acute and chronic graft rejection (48 patients with acute and 76 with chronic graft rejection) and control groups (respectively 139 and 112). The results of the study demonstrated that the allelic frequency and MDR1 genotype distribution were similar in all evaluated groups. It was revealed that MDR1 gene polymorphism was not a predisposing factor for terminal kidney failure leading to renal transplantation. Moreover, evaluation of C3435T polymorphism of MDR1 gene will probably not be useful for characterization of groups of patients at increased risk of acute and chronic kidney graft rejection.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128968346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 21

Nitric oxide in cardiac transplantation. 一氧化氮在心脏移植中的应用。

Pharmacological reports : PR Pub Date : 1900-01-01 DOI: 10.2174/1567270000502010009

W. Dietl, M. Bauer, B. Podesser

{"title":"Nitric oxide in cardiac transplantation.","authors":"W. Dietl, M. Bauer, B. Podesser","doi":"10.2174/1567270000502010009","DOIUrl":"https://doi.org/10.2174/1567270000502010009","url":null,"abstract":"The endothelium of coronary arteries has been identified as an important organ locally regulating coronary perfusion and cardiac function by paracrine secretion of nitric oxide (NO) and other vasoactive mediators. Therefore, the established organ procurement in cardiac transplantation using hypothermic storage solutions designed to preserve myocytes but not endothelial cells has to be critically discussed. Heart transplantation is a prestigious high-end treatment for end-stage heart failure patients with promising survival rates: 84% one-year and 65% five-year survival. However, these survival rates are still far from being satisfying requiring further research in organ preservation and perioperative management. This review will focus on possible strategies to improve donor and recipient management in regard to a functional endothelium and NO. The following topics will be addressed: (1) NO and ischemia/reperfusion, to understand the mechanisms that lead to NO depletion and its consequences. (2) NO and hypothermia, to understand the effects of hypothermia on the endothelium. (3) Current status of donor and recipient management, to describe the strategies used today. (4) Possible new approaches: NO-scavenging and NO-substitution, to describe the recent research that is performed in this area including some of our own results. (5) Outlook in donor and recipient management, to give possible new directions, deducted from our current knowledge.","PeriodicalId":166986,"journal":{"name":"Pharmacological reports : PR","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130098119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4